Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 2,143 | 37% |
| 2020 | 25 | 1,776 | 41% |
| 2021 | 30 |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 83% of the cases CMS names in Kentucky; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 59 | 2,308−6.2%/yr | −6.2%/yr | 5.11.0× | 3% | 2,480 in 2030+1.2%/yr |
| Hysterectomy, hysteroscopy & ablation |
BPH procedures in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Florida
| 2024 |
| 1,515 |
| 57% |
| 2025 est. | ≈ 1,280 | – |
| 2026 est. | ≈ 1,270 | – |
| 1,983 |
| 47% |
| 2022 | 22 | 1,954 | 52% |
| 2023 | 22 | 1,821 | 55% |
| 2024 | 16 | 1,515 | 57% |
| 2025 from claims | – | 1,276 1,171–1,350 | 58% |
| 2026 forecast | – | 1,273 1,120–1,469 | 59% |
| 2027 forecast | – | 1,273 1,088–1,517 | 60% |
| 2028 forecast | – | 1,273 1,062–1,558 | 60% |
| 2029 forecast | – | 1,272 1,039–1,595 | 61% |
| 2030 forecast | – | 1,271 1,018–1,629 | 62% |
In 2025, 3% inpatient hospital, 74% hospital outpatient, 5% surgery center, 18% office. The share outside the hospital has moved −11 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~1,300 | ~33 | ~970 | ~57 | ~220 |
| 2027 · ~1,300 | ~34 | ~980 | ~54 | ~210 |
| 2028 · ~1,300 | ~34 | ~980 | ~53 | ~200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 77% (74% in 2025), office about 16% (18% in 2025).
| −6.5%/yr |
| 4.5 |
| 41% |
| 9,710 in 2030−0.1%/yr |
| Georgia | 60 | 5,270−5.6%/yr | −5.6%/yr | 6.1 | 42% | 4,930 in 2030−1.1%/yr |
| Maryland | 65 | 4,904−8.2%/yr | −8.2%/yr | 5.5 | 82% | 4,770 in 2030−0.5%/yr |
| Tennessee | 62 | 4,487−4.2%/yr | −4.2%/yr | 6.3 | 43% | 4,180 in 2030−1.2%/yr |
| Virginia | 64 | 4,475+1.2%/yr | +1.2%/yr | 4.3 | 32% | 3,890 in 2030−2.3%/yr |
| North Carolina | 53 | 4,163−9.2%/yr | −9.2%/yr | 4.2 | 15% | 3,750 in 2030−1.7%/yr |
| South Carolina | 59 | 3,847−5.5%/yr | −5.5%/yr | 5.6 | 23% | 3,310 in 2030−2.5%/yr |
| Oklahoma | 41 | 2,246−10%/yr | −10%/yr | 4.6 | 36% | 2,140 in 2030−0.8%/yr |
| Mississippi | 29 | 2,122−13%/yr | −13%/yr | 5.6 | 48% | 1,630 in 2030−4.3%/yr |
| Louisiana | 22 | 1,850−5.9%/yr | −5.9%/yr | 4.5 | 30% | 1,540 in 2030−3.1%/yr |
| Arkansas | 29 | 1,636−4.1%/yr | −4.1%/yr | 4.3 | 35% | 1,550 in 2030−0.9%/yr |
| Alabama | 14 | 1,324−10%/yr | −10%/yr | 3.0 | 18% | 940 in 2030−5.5%/yr |
| Delaware | 11 | 729−4.8%/yr | −4.8%/yr | 4.2 | 45% | 790 in 2030+1.4%/yr |
| West Virginia | 11 | 613−15%/yr | −15%/yr | 2.9 | 0% | 420 in 2030−6.2%/yr |
| District of Columbia | 6 | 425−0.5%/yr | −0.5%/yr | 6.7 | 58% | 390 in 2030−1.5%/yr |
| 13 |
| 1,108−5.7%/yr |
| −5.7%/yr |
| 2.71.0× |
| 9% |
| 950 in 2030−2.6%/yr |
| Incontinence, prolapse & sacral neuromodulation | 10 | 902−8.4%/yr | −8.4%/yr | 2.00.7× | 11% | 950 in 2030+0.9%/yr |
| Prostatectomy & nephrectomy | 5 | 358−1.2%/yr | −1.2%/yr | 0.90.7× | 0% | 390 in 2030+1.4%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Teleflex leads with 43% of company spending on these surgeons in 2025, −17 pts on 2024.
In 2025, 7 companies reported engagement with Kentucky’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $719 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.